A case of palmar hypopigmentation induced by capecitabine in a gastrointestinal cancer patient. (January 2022)

• Record Type: Journal Article
• Authors: Gratiaux, Julian; Gossery, Chloé; Rezzag-Mahcene, Chirine; Botsen, Damien; Visseaux, Laetitia; Slimano, Florian; Bouche, Olivier
• Is Part Of: Journal of oncology pharmacy practice. Volume 28:Number 1(2022)
• Page Start: 247
• Page End: 249
• Publication Date: 2022-01
• Subjects: Capecitabine/fluorouracil/adverse effects -- antimetabolites -- antineoplastic/pigmentation disorders/vitiligo; Cancer -- Chemotherapy -- Periodicals; Clinical pharmacology -- Periodicals; 616.994061
• DOI: 10.1177/10781552211027936
• Languages: English
• ISSNs: 1078-1552

Abstract

Introduction: Capecitabine is an antimetabolite antineoplastic agent widely used in the treatment gastrointestinal cancers. The common frequently reported cutaneous adverse drug reaction associated with capecitabin are a palmar-plantar erythrodysesthesia syndrome, rash and hyperpigmentation. This case reports a capecitabine-induced palmar hypopigmentation. Case report: We report the case of a 74-years old patient with jejunum adenocarcinoma treated by capecitabine. The patient developed a pseudo-vitiligo after 2 cycles capecitabine and without history of cutaneous disorders. The skin lesions were characterized with skin hypopigmentation on both hands. Management and outcome: The hypopigmentation slowly recovered after capecitabine discontinuation. Conclusion: This is the first described case of pseudo-vitiligo induced by capecitabine. This impressive but non-severe adverse effect should be known by oncologists and oncology pharmacists to reassure the patients in particular about the possible recovery after discontinuation of capecitabine.